drugset / Trial / NCT05106946
Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma
Phase 1
Unknown
20 enrolled
Fundamenta Therapeutics, Ltd.
The Affiliated Hospital of Xuzhou Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
A single arm, open-label, dose-escalation study to evaluate the safety and clinical activity of ThisCART22 (Allogeneic CAR-T targeting CD22) in patients with relapsed and/or refractory non-Hodgkin's B cell lymphoma (r/r B-NHL).
Timeline
- Start
- 2021-10-25
- Primary completion
- 2023-10-25
- Completion
- 2024-10-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ThisCART22 | Cell therapy | 200000 cells/kg | — |
| Subject | ThisCART22 | Cell therapy | 6e+07 cells/kg | — |